Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Amit

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Biopharmaceutical Statistics|August 21, 2013
Evaluation of discordance measures in oncology studies with blinded independent central review of progression-free survival using an observational error modelF V Mannino, O Amit, S Lahiri
European Journal of Cancer (Oxford, England : 1990)|March 25, 2011
Blinded independent central review of progression in cancer clinical trials: results from a meta-analysisO Amit, F Mannino, A M Stone, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2011
Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working groupA M Stone, W Bushnell, J Denne, et al.
Physical Review Letters|September 7, 2019
T^{3} Stern-Gerlach Matter-Wave InterferometerO Amit, Y Margalit, O Dobkowski, et al.
Lancet (London, England)|August 11, 2001
Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging studyC H Compton, J Gubb, R Nieman, et al.
Clinical Pharmacology and Therapeutics|January 1, 1997
DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartanM R Goldberg, M W Lo, D D Christ, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Biopharmaceutical Statistics|August 21, 2013
Evaluation of discordance measures in oncology studies with blinded independent central review of progression-free survival using an observational error modelF V Mannino, O Amit, S Lahiri
European Journal of Cancer (Oxford, England : 1990)|March 25, 2011
Blinded independent central review of progression in cancer clinical trials: results from a meta-analysisO Amit, F Mannino, A M Stone, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2011
Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working groupA M Stone, W Bushnell, J Denne, et al.
Physical Review Letters|September 7, 2019
T^{3} Stern-Gerlach Matter-Wave InterferometerO Amit, Y Margalit, O Dobkowski, et al.
Lancet (London, England)|August 11, 2001
Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging studyC H Compton, J Gubb, R Nieman, et al.
Clinical Pharmacology and Therapeutics|January 1, 1997
DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartanM R Goldberg, M W Lo, D D Christ, et al.
Pageof 1